JP4354725B2 - 結腸直腸癌の評価 - Google Patents
結腸直腸癌の評価 Download PDFInfo
- Publication number
- JP4354725B2 JP4354725B2 JP2003094744A JP2003094744A JP4354725B2 JP 4354725 B2 JP4354725 B2 JP 4354725B2 JP 2003094744 A JP2003094744 A JP 2003094744A JP 2003094744 A JP2003094744 A JP 2003094744A JP 4354725 B2 JP4354725 B2 JP 4354725B2
- Authority
- JP
- Japan
- Prior art keywords
- genes
- gene
- portfolio
- gene expression
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims description 23
- 206010009944 Colon cancer Diseases 0.000 title claims description 22
- 238000011156 evaluation Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 121
- 238000003745 diagnosis Methods 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 238000010208 microarray analysis Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 75
- 238000000034 method Methods 0.000 description 38
- 239000000523 sample Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 21
- 238000002493 microarray Methods 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 16
- 238000005259 measurement Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000012340 reverse transcriptase PCR Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000037051 Chromosomal Instability Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 102100037965 60S ribosomal protein L21 Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 108090000327 ribosomal protein L21 Proteins 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007278 Carcinoid tumour of the caecum Diseases 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 102000000820 Enterotoxin Receptors Human genes 0.000 description 1
- 108010001687 Enterotoxin Receptors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 description 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000020250 cecum neuroendocrine tumor G1 Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000012567 pattern recognition method Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36868702P | 2002-03-29 | 2002-03-29 | |
| US60/368687 | 2002-03-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009086981A Division JP2009153521A (ja) | 2002-03-29 | 2009-03-31 | 結腸直腸癌の評価 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003325191A JP2003325191A (ja) | 2003-11-18 |
| JP2003325191A5 JP2003325191A5 (enExample) | 2006-03-09 |
| JP4354725B2 true JP4354725B2 (ja) | 2009-10-28 |
Family
ID=28675528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003094744A Expired - Fee Related JP4354725B2 (ja) | 2002-03-29 | 2003-03-31 | 結腸直腸癌の評価 |
| JP2009086981A Pending JP2009153521A (ja) | 2002-03-29 | 2009-03-31 | 結腸直腸癌の評価 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009086981A Pending JP2009153521A (ja) | 2002-03-29 | 2009-03-31 | 結腸直腸癌の評価 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030186303A1 (enExample) |
| EP (1) | EP1355151A3 (enExample) |
| JP (2) | JP4354725B2 (enExample) |
| KR (1) | KR100984996B1 (enExample) |
| CN (2) | CN101684500A (enExample) |
| AR (1) | AR039211A1 (enExample) |
| AU (1) | AU2003203561A1 (enExample) |
| BR (1) | BR0303012A (enExample) |
| CA (1) | CA2422305C (enExample) |
| MX (1) | MXPA03002863A (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2475769C (en) * | 2003-08-28 | 2018-12-11 | Veridex, Llc | Colorectal cancer prognostics |
| US20050153352A1 (en) * | 2004-01-09 | 2005-07-14 | Stanley Chang | Cancer specific gene MG20 |
| CA2610709A1 (en) * | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
| TW200730825A (en) * | 2005-10-21 | 2007-08-16 | Genenews Inc | Method and apparatus for correlating levels of biomarker products with disease |
| CN101437962A (zh) * | 2006-03-03 | 2009-05-20 | 维里德克斯有限责任公司 | 预测杜克氏b结肠癌复发的分子检测 |
| CN102099485A (zh) * | 2007-10-23 | 2011-06-15 | 临床基因组学有限公司 | 诊断新生物的方法-ⅱ |
| EP2169078A1 (en) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Methods and kits for the diagnosis and the staging of colorectal cancer |
| WO2013092960A1 (en) | 2011-12-22 | 2013-06-27 | Fundacion Gaiker | Methods and kits for the diagnosis of colorectal cancer |
| CN102586420B (zh) * | 2011-12-27 | 2014-10-22 | 盛司潼 | 一种检测乳腺癌易感基因的方法及试剂盒 |
| CN102586423B (zh) * | 2011-12-27 | 2015-01-07 | 盛司潼 | 一种检测结直肠癌易感基因的方法及试剂盒 |
| CN115678994B (zh) * | 2022-01-27 | 2025-01-21 | 上海爱谱蒂康生物科技有限公司 | 一种生物标志物组合、含其的试剂及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US635152A (en) * | 1899-06-05 | 1899-10-17 | Melancthon S Shotwell | Car-body bolster. |
| US6275814B1 (en) * | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) * | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| US6350578B1 (en) * | 1999-06-25 | 2002-02-26 | The Regents Of The University Of California | Method of quantitating dsDNA |
| US6175824B1 (en) * | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
-
2003
- 2003-03-21 US US10/394,382 patent/US20030186303A1/en not_active Abandoned
- 2003-03-28 BR BR0303012-1A patent/BR0303012A/pt not_active IP Right Cessation
- 2003-03-28 CA CA2422305A patent/CA2422305C/en not_active Expired - Fee Related
- 2003-03-28 AU AU2003203561A patent/AU2003203561A1/en not_active Abandoned
- 2003-03-29 KR KR1020030019815A patent/KR100984996B1/ko not_active Expired - Fee Related
- 2003-03-29 CN CN200910175739A patent/CN101684500A/zh active Pending
- 2003-03-29 CN CNA031378714A patent/CN1502989A/zh active Pending
- 2003-03-31 JP JP2003094744A patent/JP4354725B2/ja not_active Expired - Fee Related
- 2003-03-31 EP EP03252024A patent/EP1355151A3/en not_active Withdrawn
- 2003-03-31 MX MXPA03002863A patent/MXPA03002863A/es active IP Right Grant
- 2003-04-01 AR ARP030101132A patent/AR039211A1/es not_active Application Discontinuation
-
2009
- 2009-03-31 JP JP2009086981A patent/JP2009153521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003203561A1 (en) | 2003-10-23 |
| CA2422305A1 (en) | 2003-09-29 |
| AR039211A1 (es) | 2005-02-09 |
| JP2003325191A (ja) | 2003-11-18 |
| BR0303012A (pt) | 2004-09-08 |
| KR20030078801A (ko) | 2003-10-08 |
| CN1502989A (zh) | 2004-06-09 |
| KR100984996B1 (ko) | 2010-10-04 |
| CA2422305C (en) | 2013-07-30 |
| EP1355151A3 (en) | 2004-08-25 |
| EP1355151A2 (en) | 2003-10-22 |
| CN101684500A (zh) | 2010-03-31 |
| JP2009153521A (ja) | 2009-07-16 |
| US20030186303A1 (en) | 2003-10-02 |
| MXPA03002863A (es) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4913331B2 (ja) | 結腸直腸癌の予後 | |
| JP2009153521A (ja) | 結腸直腸癌の評価 | |
| US8183353B2 (en) | Breast cancer prognostics | |
| JP2009153522A (ja) | 結腸直腸癌の評価 | |
| US20100009371A1 (en) | Selection of markers | |
| US20090221445A1 (en) | Cancer Diagnostic Panel | |
| EP1888785A2 (en) | Thyroid fine needle aspiration molecular assay | |
| JP2004537261A (ja) | 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング | |
| AU2008203227B2 (en) | Colorectal cancer prognostics | |
| US20050186577A1 (en) | Breast cancer prognostics | |
| EP1367138B1 (en) | Markers for breast cancer prognosis | |
| EP1512758B1 (en) | Colorectal cancer prognostics | |
| EP1683862B1 (en) | Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis | |
| Horlings et al. | Clinical Genomics in Oncology | |
| EP1679382A2 (en) | Panel of nucleic acid sequences for cancer diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090106 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090331 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090421 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090630 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090730 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120807 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130807 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |